BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Steiner S, Daniel C, Fischer A, Atreya I, Hirschmann S, Waldner M, Neumann H, Neurath M, Atreya R, Weigmann B. Cyclosporine A regulates pro-inflammatory cytokine production in ulcerative colitis. Arch Immunol Ther Exp (Warsz). 2015;63:53-63. [PMID: 25155925 DOI: 10.1007/s00005-014-0309-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Lee SH, Kwon JE, Cho ML. Immunological pathogenesis of inflammatory bowel disease. Intest Res. 2018;16:26-42. [PMID: 29422795 DOI: 10.5217/ir.2018.16.1.26] [Cited by in Crossref: 128] [Cited by in F6Publishing: 123] [Article Influence: 32.0] [Reference Citation Analysis]
2 Yoo JH, Donowitz M. Intestinal enteroids/organoids: A novel platform for drug discovery in inflammatory bowel diseases. World J Gastroenterol 2019; 25(30): 4125-4147 [PMID: 31435168 DOI: 10.3748/wjg.v25.i30.4125] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
3 Sato H, Kaneko Y, Yamada K, Ristroph KD, Lu HD, Seto Y, Chan H, Prud’homme RK, Onoue S. Polymeric Nanocarriers With Mucus-Diffusive and Mucus-Adhesive Properties to Control Pharmacokinetic Behavior of Orally Dosed Cyclosporine A. Journal of Pharmaceutical Sciences 2020;109:1079-85. [DOI: 10.1016/j.xphs.2019.10.043] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
4 Giuffrida P, Di Sabatino A. Targeting T cells in inflammatory bowel disease. Pharmacol Res. 2020;159:105040. [PMID: 32585338 DOI: 10.1016/j.phrs.2020.105040] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
5 Lechner K, Zeeshana M, Noack M, Ali H, Neurath M, Weigmanna B. Small but powerful: Will nanoparticles be the future state‐of‐the‐art therapy for IBD? Expert Opinion on Drug Delivery. [DOI: 10.1080/17425247.2022.2043847] [Reference Citation Analysis]
6 Neurath MF. Current and emerging therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol. 2017;14:269-278. [PMID: 28144028 DOI: 10.1038/nrgastro.2016.208] [Cited by in Crossref: 214] [Cited by in F6Publishing: 208] [Article Influence: 42.8] [Reference Citation Analysis]
7 Ding Q, Zhou H, Yun B, Zhou L, Zhang N, Yin G, Fan J. Interleukin-13 Inhibits Expression of cyp27b1 in Peripheral CD14+ Cells That Is Correlated With Vertebral Bone Mineral Density of Patients With Ulcerative Colitis. J Cell Biochem 2017;118:376-81. [PMID: 27381199 DOI: 10.1002/jcb.25646] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]